| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C20H15ClFN3O |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor, with IC50 values of 50 nM for p38α and 100 nM for p38β2, and binds the ATP pocket of active recombinant human p38 kinase with a Kd of 38 nM. It has anti-cancer activity[1][2] and induces autophagy. It is supplied as a light yellow to yellow solid (C20H15ClFN3O, MW 367.80) at 99.60% purity.
Physical & Chemical Properties
| CAS Number | 350228-36-3 |
|---|---|
| Molecular Formula | C20H15ClFN3O |
| Molecular Weight | 367.80 g/mol |
| Purity | 99.60% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | OC1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1.[H]Cl |
| Target | p38α, p38β2 |
| Signaling Pathway | Stem Cell/Wnt; MAPK/ERK Pathway; Autophagy; Apoptosis |
| Solubility | In Vitro: DMSO: 83.33 mg/mL (226.56 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | -20°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
p38α 50 nM (IC50) |
p38β2 100 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 83.33 mg/mL (226.56 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
Growth of a subgroup of CRC cell lines, such as RKO, CACO2, and SW480, is attenuated by SB 202190 hydrochloride (0-10 μM; 0-72 hours) in a dose- and time-dependent manner[1]. In this same subset of CRC lines (RKO, CACO2, and SW480), SB 202190 hydrochloride strongly suppresses colony formation and anchorage-independent growth (10 μM for 7-10 days) and increases apoptotic cell death (10 μM for 72 h)[2]. SB 202190 (10 μM; 2 hours) hydrochloride abrogates S6K1(T389) and S6(S235/236) phosphorylation in RKO, CACO2, and SW480 cells, while AKT(S473) phosphorylation is spared, which indicates selective blockade of mTORC1 signaling by p38i[2].
In Vivo
At 5 mg/kg (intraperitoneal injection; daily for 10-12 days), SB 202190 hydrochloride inhibits tumor cell survival and tumor growth[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Steatosis shapes prognosis-defining liver metastasis heterogeneity in CRC. Nature 2026 Aug;656(8126):207-215. PMID: 42386979
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer Cell 2026 May 21:S1535-6108(26)00220-5. PMID: 42167227
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. Cancer Cell 2024 Dec 9;42(12):2015-2031.e11. PMID: 39577420
Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma. Cancer Cell 2023 Jun 12;41(6):1103-1117.e12. PMID: 37207655
mTOR activity paces human blastocyst stage developmental progression. Cell 2024 Nov 14;187(23):6566-6583.e22. PMID: 39332412
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Mol Cancer 2024 Jan 10;23(1):12. PMID: 38200517
Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution. Mol Cancer 2023 Jan 24;22(1):17. PMID: 36691028
Nat Photonics. 2025 Jul 10.
Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res 2020 Jul;30(7):574-589.
Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity 2022 Nov 8;55(11):2059-2073.e8. PMID: 36351375
